Delayed-Release Dimethyl Fumarate and Pregnancy: Preclinical Studies and Pregnancy Outcomes from Clinical Trials and Postmarketing Experience

Neurology and Therapy

Volumn 4, Issue 2, 2015, Pages 93-104

  Gold, Ralf ^a   Phillips, J Theodore ^b   Havrdova, Eva ^c   Bar Or, Amit ^d   Kappos, Ludwig ^e   Kim, Norman ^f   Thullen, Tim ^f   Valencia, Patricia ^f   Oliva, Lauren ^f   Novas, Mark ^f   Li, Jie ^f   Sweetser, Marianne T ^f,g   Kurukulasuriya, Nuwan ^f   Viglietta, Vissia ^f   Fox, Robert J ^h  

^a ST JOSEF HOSPITAL   (Germany)

^b BAYLOR INSTITUTE FOR IMMUNOLOGY RESEARCH   (United States)

^c CHARLES UNIVERSITY   (Czech Republic)

^d MCGILL UNIVERSITY   (Canada)

^e UNIVERSITY HOSPITAL BASEL   (Switzerland)

^f BIOGEN   (United States)

^g ALNYLAM PHARMACEUTICALS   (United States)

^h LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Clinical trial; Delayed release dimethyl fumarate; Multiple sclerosis; Postmarketing; Preclinical; Pregnancy; Safety; Women

Indexed keywords

FUMARIC ACID DIMETHYL ESTER;

ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DELAYED RELEASE FORMULATION; FEMALE; FERTILITY; FETUS DISEASE; FOLLOW UP; FOOD INTAKE; HUMAN; INCIDENCE; LIVE BIRTH; MULTIPLE SCLEROSIS; NONHUMAN; NUTRITIONAL STATUS; POSTMARKETING SURVEILLANCE; PREGNANCY OUTCOME; PREGNANCY TERMINATION; PREGNANT WOMAN; PRENATAL DEVELOPMENT; PRIORITY JOURNAL; PSORIASIS; RHEUMATOID ARTHRITIS; SPONTANEOUS ABORTION; SURVIVAL RATE; TERATOGENICITY;

EID: 84977134291     PISSN: 21938253     EISSN: 21936536     Source Type: Journal    
DOI: 10.1007/s40120-015-0033-1     Document Type: Article

References (33)

1. Tullman MJ. Overview of the epidemiology, diagnosis, and disease progression associated with multiple sclerosis. Am J Manag Care. 2013;19:S15–20.
2. Lu E, Wang BW, Synnes A, Dahlgren L, Sadovnick AD, Tremlett H. A review of safety-related pregnancy data surrounding the oral disease-modifying drugs for multiple sclerosis. CNS Drugs. 2014;28:89–94.
3. Lu E, Wang BW, Guimond C, et al. Safety of disease-modifying drugs for multiple sclerosis in pregnancy: current challenges and future considerations for effective pharmacovigilance. Expert Rev Neurother. 2013;13(3):251–61.
4. Coyle PK, Christie S, Fodor P, et al. Multiple sclerosis gender issues: clinical practices of women neurologists. Mult Scler. 2004;10:582–8.
5. Langer-Gould AM. The pill times 2: what every woman with multiple sclerosis should know. Neurology. 2014;82:1–2.
6. Fragoso YD, Boggild M, Macias-Islas MA, et al. The effects of long-term exposure to disease-modifying drugs during pregnancy in multiple sclerosis. Clin Neurol Neurosurg. 2013;115:154–9.
7. Tecfidera (dimethyl fumarate) prescribing information. Cambridge: Biogen Inc.; 2013. http://www.tecfidera.com/pdfs/full-prescribing-information.pdf. Accessed Oct 21, 2014.
8. Linker RA, Lee DH, Ryan S, et al. Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. Brain. 2011;134:678–92.
9. Scannevin RH, Chollate S, Jung MY, et al. Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway. J Pharmacol Exp Ther. 2012;341:274–84.
10. Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367(12):1098–107.
11. Fox RJ, Miller DH, Phillips T, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med. 2012;367(12):1087–97.
12. International Conference on Harmonisation [ICH] S5(R2) guideline: Detection of Toxicity to Reproduction for Medicinal Products & Toxicity to Male Fertility, current Step 4 version. 2005.
13. Chahoud I, Buschmann J, Clark R, et al. Classification terms in developmental toxicology: need for harmonization. Report of the second workshop on the terminology in developmental toxicology. Reprod Toxicol. 1999;13(1):77–82.
14. Chahoud I, Paumgartten FJR. Relationships between fetal body weight of Wistar rats at term and the extent of skeletal ossification. Braz J Med Biol Res. 2005;38:565–75.
15. Carney EW, Kimmel CA. Interpretation of skeletal variations for human risk assessment: delayed ossification and wavy ribs. Birth Defects Res B Dev Reprod Toxicol. 2007;80(6):473–96.
16. Matsuzawa T, Nakata M, Goto I, Tsushima M. Dietary deprivation induces fetal loss and abortion in rabbits. Toxicology. 1981;22(3):255–9.
17. Clark RL, Antonello JM, Wenger JD, Deverle-Brooks K, Duchai DM. Selection of food allotment for New Zealand white rabbits in developmental toxicity studies. Fundam Appl Toxicol. 1991;17(3):584–92.
18. Matsuoka T, Mizoguchi Y, Serizawa K, Ishikura T, Mizuguchi H, Asano Y. Effects of stage and degree of restricted feeding on pregnancy outcome in rabbits. J Toxicol Sci. 2006;31(2):169–75.
19. Cappon GD, Fleeman TL, Chapin RE, Hurtt ME. Effects of feed restriction during organogenesis on embryo-fetal development in rabbit. BDR(B). 2006;74:424–30.
20. Prentice DE, Meikle AW. A review of drug-induced Leydig cell hyperplasia and neoplasia in the rat and some comparisons with man. Hum Exp Toxicol. 1995;14(7):562–72.
21. Cook JC, Klinefelter GR, Hardisty JF, Sharpe RM, Foster PM. Rodent Leydig cell tumorigenesis: a review of the physiology, pathology, mechanisms, and relevance to humans. Crit Rev Toxicol. 1999;29(2):169–261.
22. Clegg ED, Cook JC, Chapin RE, Foster PM, Daston GP. Leydig cell hyperplasia and adenoma formation: mechanisms and relevance to humans. Reprod Toxicol. 1997;11(1):107–21.
23. Zaw W, Stone DG. Caudal regression syndrome in twin pregnancy with type II diabetes. J Perinatol. 2002;22(2):171–4.
24. Litjens NH, van Strijen E, van Gulpen C, et al. In vitro pharmacokinetics of anti-psoriatic fumaric acid esters. BMC Pharmacol. 2004;4:22. doi:10.1186/1471-2210-4-22.
25. García-Enguídanos A, Calle ME, Valero J, Luna S, Domínguez-Rojas V. Risk factors in miscarriage: a review. Eur J Obstet Gynecol Reprod Biol. 2002;102(2):111–9.
26. Gilenya (fingolimod) prescribing information. East Hanover: Novartis International AG; 2014. http://www.pharma.us.novartis.com/product/pi/pdf/gilenya.pdf. Accessed Oct 21, 2014.
27. Aubagio (teriflunomide) prescribing information. Cambridge: Genzyme Corporation, a Sanofi company; 2012. http://products.sanofi.us/aubagio/aubagio.pdf. Accessed Oct 21, 2014.
28. Karlsson G, Francis G, Koren G, et al. Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis. Neurology. 2014;82:674–80.
29. Weber-Schoendorfer C, Schaefer C. Multiple sclerosis, immunomodulators, and pregnancy outcome: a prospective observational study. Mult Scler. 2009;15:1037–42.
30. Amato MP, Portaccio E, Ghezzi A, et al. Pregnancy and fetal outcomes after interferon-β exposure in multiple sclerosis. Neurology. 2010;75:1794–802.
31. Houtchens MK, Kolb CM. Multiple sclerosis and pregnancy: therapeutic considerations. J Neurol. 2013;260:1202–14.
32. Dahl J, Myhr KM, Daltveit AK, Gilhus NE. Pregnancy, delivery and birth outcome in different stages of maternal multiple sclerosis. J Neurol. 2008;255(6):623–7.
33. Lu E, Wang BW, Guimond C, Synnes A, Sadovnick D, Tremlett H. Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review. Neurology. 2012;79(11):1130–5.